Lyell Immunopharma – Talk Bio

Actionable Insights Powered by AI

AnaptysBio Halts Phase 2 Ulcerative Colitis Trial; Lyell Immunopharma Secures CAR-T Rights

1 month ago talkbio0Tagged AnaptysBio, CAR-T therapy, Clinical Failure, Clinical Trials, Discontinuation (procedure), Lyell Immunopharma, News [Publication Type], Phase 2 trial, Rheumatoid Arthritis, Rosnilimab, Ulcerative Colitis

AnaptysBio; rosnilimab; ulcerative colitis; Phase 2 trial; clinical failure; trial discontinuation; Lyell Immunopharma; CAR-T therapy; licensing deal; biotech news; rheumatoid arthritis

Lyell Immunopharma Acquires ImmPACT Bio to Bolster CAR T-cell Therapy Pipeline

1 year ago talkbio0Tagged Autoimmune Diseases, Automobiles, Bio, Biotechnology, Cancer Therapeutic Procedure, Lyell Immunopharma, pipeline acquisition, T-cell therapy

Lyell Immunopharma, ImmPACT Bio, CAR T-cell therapy, pipeline acquisition, biotechnology, cancer treatment, autoimmune diseases